UNSPSC 51401704: Febarbamate

This classification denotes an anticonvulsant agent with the molecular formula C20H27N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z48ONN38P, chemically known as 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid, carbamate ester but generally known as febarbamate, which bears US NIH Compound Identifier 25803. European Medicines Agency schedules Febarbamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07519MIG.

UNSPSC 51401704 Febarbamate (Commodity) shows minimal relevant recent activity; state and local procurement records tag opportunities under this code that address naloxone, drug deactivation systems, pharmacy benefit program direct-to-manufacturer contracting, and generic multi-source pharmaceutical distribution — none of which are febarbamate products. The code's nominal scope (febarbamate, a specific pharmaceutical compound) does not align with the diverse pharmaceutical and health-system procurement activity appearing in recent solicitations. State and local governments buying under this designation are primarily counties and state health agencies addressing opioid crisis response, pharmacy benefit administration, and bulk pharmaceutical supply through cooperative purchasing vehicles, but the mismatch between the code definition and actual solicitation scope suggests either data-entry error or a code applied inconsistently across jurisdictions.

Recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, response due July 26, 2023) for naloxone and drug deactivation systems procured through the county's e-Procurement Portal with quarterly deliveries and fixed-fee pricing; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) for direct-to-manufacturer prescription program vendor capabilities, a preliminary market-intelligence step preceding formal RFP; and the Minnesota Multistate Cooperative Purchasing Alliance's S1070000015802 (posted January 20, 2026, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local facilities across Minnesota and Oregon. The febarbamate code lacks coherent recent activity aligned with its stated product scope and does not merit pursuit under current market signals.